A5029001811- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Cancer and Skin Lesions
- HER2/EGFR in Cancer Research
- Breast Lesions and Carcinomas
- Advanced Breast Cancer Therapies
- Pancreatic and Hepatic Oncology Research
- Metabolism and Genetic Disorders
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Stress Responses and Cortisol
- Cancer Research and Treatments
- Neuroendocrine Tumor Research Advances
- Cancer Diagnosis and Treatment
- Hormonal Regulation and Hypertension
- Head and Neck Cancer Studies
- Adrenal Hormones and Disorders
- Cervical Cancer and HPV Research
- Liver Disease Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Clinical Nutrition and Gastroenterology
- Immune Cell Function and Interaction
- Hematological disorders and diagnostics
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
University of Verona
2020-2022
Azienda Ospedaliera di Padova
2018-2021
University Hospital Foundation
2021
University of Padua
2018-2020
Santa Maria Nuova Hospital
2019-2020
Istituto Oncologico Veneto
2018-2019
Istituti di Ricovero e Cura a Carattere Scientifico
2018-2019
Military Medical Academy
1977
Abstract Although 1% is the recommended cut-off to define estrogen receptor (ER) positivity, a 10% often used in clinical practice for therapeutic purposes. We here evaluate outcomes according ER levels monoinstitutional cohort of non-metastatic triple-negative breast cancer (BC) patients undergoing (neo)adjuvant chemotherapy. Clinicopathological data 406 with < HER2-negative BC treated chemotherapy between 01/2000 and 04/2019 were collected. Patients categorized ER-negative (ER 1%; N =...
Tumor-infiltrating lymphocytes (TILs) evaluated in primary breast cancer (BC) convey prognostic information. Limited data the metastatic setting are available. Secondary lesions from 94 BC patients, 43 triple-negative (TN) and 51 HER2-positive, were for TILs expression of CD8, FOXP3, PD-L1 by immunohistochemistry. levels on metastasis generally low (median 5%) did not differ between TN HER2+ tumors. Younger patients showed significantly lower (p = 0.002). In higher lung metastases as...
Background. We evaluated immunohistochemical AR expression and correlation with prognosis in a large series of homogeneously treated patients primary TNBC. Material methods. Patients diagnosed stage I-III TNBC between 2000 2015 at Istituto Oncologico Veneto who received treatment surgery neoadjuvant and/or adjuvant chemotherapy were included. Whole tissue slides stained for AR. AR-positive was defined as >1% positively tumor cells. Distant-disease-free survival (DDFS) calculated from...
Tumour infiltrating lymphocytes (TILs) are an established prognostic biomarker for triple-negative breast cancer (TNBC). We evaluated the role of programmed cell-death ligand-1 (PD-L1), CD8 and FOXP3 expression in refining a model non-metastatic TNBC beyond classic factors TILs.Primary tumour samples from 244 early patients with TNBC, all treated surgery chemotherapy, were collected. Stromal TILs on haematoxylin-eosin slides according to guidelines. PD-L1, assessed by immunohistochemistry...
Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that heterogeneity in response seen partly explained by levels gene (ERBB2) mRNA. We analyzed ERBB2 expression using a clinically applicable assay formalin-fixed paraffin-embedded (FFPE) tumors (primary or metastatic) from...
BackgroundPhyllodes tumours (PTs) are rare fibroepithelial accounting for <1% of all breast tumours. We assessed clinicopathological features and their prognostic effect in a single-institution patients' cohort.MethodsPatients diagnosed with PT between 2001 2018 at our institution were identified. Clinical, surgical pathological collected. Phyllodes-related relapse was defined as locoregional or distant recurrence (contralateral excluded), whichever first.ResultsA total 166 patients...
Abstract Background The integration of residual cancer burden (RCB) and post-treatment Ki67 as proliferative (RPCB) has been proposed a stronger predictor long-term outcome in unselected patients with breast (BC) undergoing neoadjuvant chemotherapy (NACT), compared RCB. However, no specific analysis hormone-receptor-positive (HR+) human epidermal growth receptor 2-negative (HER2−) BC is available so far. Materials Methods A cohort 130 HR+/HER2− who underwent NACT between 2000 2014 was...
Breast Cancer (BC) skin metastases represent a challenging clinical scenario. Although they usually arise when other distant are already present, may also form of locoregional recurrence (LRR). Systemic therapy in this setting have role both case radical approach is unfeasible order to achieve disease control, and as adjuvant strategy after removal cutaneous lesions, prevent or delay subsequent spread. for HER2+ metastatic BC (MBC) currently relies on anti-HER2 targeted agents. In context...
Mixed neuroendocrine/non-neuroendocrine neoplasms (MiNEN) are rare mixed epithelial in which a neuroendocrine component is combined with non-neuroendocrine component. Here, we provide the clinical, pathologic, and molecular report of 73-year-old-man presenting an intestinal MiNEN. The lesion was composed well-differentiated G3 tumor colloid adenocarcinoma. characterization performed using multigene next-generation sequencing panel. neoplasm displayed microsatellite instability due to MLH1...
Abstract Background: Targeting the PD-L1/PD-1 axis has proved to be effective in various cancers, including promising data for metastatic TNBC pts. The evaluation of PD-L1 expression is limited by lack standardized methods. Here we sought evaluate prognostic role a large cohort patients with non-metastatic treated standard therapy. Methods: Consecutive diagnosed stage I-III (ER and PgR &lt;10%, HER2 0/1+ or ISH non amplified) between May 2012 December 2015 at Istituto Oncologico Veneto...
The present study reports the case of an axillary hibernoma in a patient with lobular homolateral breast cancer and multiple endocrine neoplasia type1 (MEN-1). Hibernoma is rare benign adipose tissue tumor, usually manifests as slowly growing painless rubbery mass. These tumors can arise various sites, but mammary hibernomas remain extraordinarily uncommon. Although are metabolically active therefore "glucose-avid" on fluorodeoxyglucose CT-positron emission tomography (FDG CT-PET), imaging...
SummaryDaily fluctuations in plasma Cortisol levels were studied three groups of children with rheumatoid arthritis. One group was untreated hormones, the second treated a depot preparation tetracosactrin, and third corticosteroid hormones. The results obtained compared rhythm normal children. daily arthritis who did not receive hormonal treatment differed from those by presence two distinct characteristic levels: apeak between 8 a.m. 12 noon minimal level 4 p.m. midnight (with gradual rise...
In order to assess the effect of ACTH on adrenal cortex when used as a therapeutic or diagnostic agent, adrenocortical function was tested before and 2 hours after 0.5 mg tetracosactrin given intramuscularly in 31 healthy children, divided into 4 groups according age sex. Mean plasma cortisol levels were shown be 184% higher than baseline values administration drug, there no significant differences related It is suggested that this simple test can practical value diagnosis young people.
Pilomatricoma is a relatively common benign cutaneous adnexal tumor and well-recognized entity, while its pigmented variant far less reported. Its estimated frequency ranges from 11 to 24%, according limited number of published case series. This article describes the 42-year-old man presenting firm subcutaneous nodule periareolar region. Histopathologic examination revealed cystic lesion composed matrical supramatrical cells accompanied by foreign body granulomatous cell reaction....
Introduction Low-grade adenosquamous breast cancer (ASBC) is a rare histological subtype of metaplastic cancer. Even tough it triple negative cancer, characterised by good prognosis, low probability distant metastases and higher risk local relapses. Clinical Case This clinical case 65-year-old woman with retroareolar nodule on the left breast. After examination diagnosis low-grade was established. Further lymph nodes showed regional metastasis ASBC. Discussion Due to its specific growth...
Breast cancer (BC) is a heterogeneous disease including multiple histological subtypes with different biological behavior and clinical outcome for the patient. Due to its heterogeneity, BC classified into groups, providing possibilities target therapies improving – histological, TNM classification, molecular classification. The proposed at beginning by Perou et al in 2000, divides 5 - Luminal A, B, HER 2 enriched, claudin-low basal like. More attention should be paid further classification...
Abstract Background: Although 1% is recommended by guidelines as cut-off for estrogen receptor (ER) positivity, the 10% often used in clinical practice based on studies showing that breast cancers with ER ≥1% &&lt;10% have biological characteristics and prognosis similar to those &lt;1%. Our aim was compare disease-free survival (DFS) overall (OS) according level a cohort of patients HER2-negative, ER&lt;10% progesterone &lt;10% undergoing (neo)adjuvant chemotherapy....
Abstract Background: The integration of Residual Cancer Burden (RCB) and post-treatment Ki67 (Residual Proliferative [RPCB] index) has been proposed as a stronger predictor long-term outcome in unselected breast cancer (BC) patients undergoing neoadjuvant chemotherapy (NACT), compared to RCB. However, no specific analysis the subgroup with hormone-receptor (HR)-positive/HER2-negative BC is available so far. We investigated prognostic value RPCB an independent cohort (HR) positive/HER2...
Abstract Background: Tumor infiltrating lymphocytes (TILs) are strong prognostic biomarkers for early TNBC. We evaluated the role of CD8, FOXP3 and PD-L1 expression in refining models non-metastatic TNBC a large cohort patients treated with standard therapy. Methods: Consecutive diagnosed stage I-III (ER/PgR &lt;10%, HER2 0/1+ or ISH non amplified) between May 2012 December 2015 were included. All received treatment surgery, chemotherapy (neoadjuvant adjuvant) radiotherapy (when...